IKZF5

Summary

IKZF5 (IKAROS family zinc finger 5, HGNC:14283) is a protein-coding gene on chromosome 10q26.13, encoding Zinc finger protein Pegasus (Q9H5V7). Transcriptional repressor that binds the core 5’GNNTGTNG-3’ DNA consensus sequence.

Members of the Ikaros (ZNFN1A1; MIM 603023) family of transcription factors, which includes Pegasus, are expressed in lymphocytes and are implicated in the control of lymphoid development.

Source: NCBI Gene 64376 — RefSeq curated summary.

At a glance

• Gene–disease (curated): thrombocytopenia 7 (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 32 total — 2 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 9
• MANE Select transcript: NM_001372123

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14283
Approved symbol	IKZF5
Name	IKAROS family zinc finger 5
Location	10q26.13
Locus type	gene with protein product
Status	Approved
Aliases	Pegasus, FLJ22973
Ensembl gene	ENSG00000095574
Ensembl biotype	protein_coding
OMIM	606238
Entrez	64376

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 14 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000368886, ENST00000469821, ENST00000479103, ENST00000496605, ENST00000617859, ENST00000904850, ENST00000904851, ENST00000904852, ENST00000904853, ENST00000904854, ENST00000904855, ENST00000904856, ENST00000904857, ENST00000934440, ENST00000934441, ENST00000934442, ENST00000934443

RefSeq mRNA: 10 — MANE Select: NM_001372123 NM_001271840, NM_001372123, NM_001372124, NM_001372125, NM_001372126, NM_001372127, NM_001372128, NM_001372129, NM_001372130, NM_001372131

CCDS: CCDS41574

Canonical transcript exons

ENST00000368886 — 5 exons

Exon	Start	End
ENSE00001016085	123007026	123007176
ENSE00001448203	122990807	122994723
ENSE00001889065	123008694	123008795
ENSE00003550778	122995994	122996176
ENSE00003643508	122998493	122998671

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 88.97.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.6855 / max 215.3042, expressed in 1763 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
111774	12.3075	1761
111773	0.3780	140

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	88.97	gold quality
body of pancreas	UBERON:0001150	86.70	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.40	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.13	gold quality
left ovary	UBERON:0002119	85.97	gold quality
pancreas	UBERON:0001264	85.54	gold quality
monocyte	CL:0000576	85.52	gold quality
mononuclear cell	CL:0000842	85.38	gold quality
islet of Langerhans	UBERON:0000006	85.32	gold quality
ovary	UBERON:0000992	85.24	gold quality
leukocyte	CL:0000738	85.20	gold quality
spinal cord	UBERON:0002240	85.02	gold quality
skin of abdomen	UBERON:0001416	84.87	gold quality
mammary duct	UBERON:0001765	84.54	gold quality
right lobe of liver	UBERON:0001114	84.35	gold quality
germinal epithelium of ovary	UBERON:0001304	84.26	gold quality
right ovary	UBERON:0002118	84.26	gold quality
gastrocnemius	UBERON:0001388	84.24	gold quality
rectum	UBERON:0001052	84.22	gold quality
cerebellar hemisphere	UBERON:0002245	84.16	gold quality
cerebellar cortex	UBERON:0002129	84.07	gold quality
bone marrow	UBERON:0002371	83.88	gold quality
tibial nerve	UBERON:0001323	83.83	gold quality
muscle of leg	UBERON:0001383	83.77	gold quality
corpus callosum	UBERON:0002336	83.70	gold quality
skin of leg	UBERON:0001511	83.52	gold quality
right hemisphere of cerebellum	UBERON:0014890	83.51	gold quality
mucosa of stomach	UBERON:0001199	83.45	gold quality
right lung	UBERON:0002167	83.31	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.80

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
LNPEP	Activation

Literature-anchored findings (GeneRIF, showing 2)

• IKZF5 is a novel transcriptional regulator of megakaryopoiesis and the eighth transcription factor associated with dominant thrombocytopenia in humans. (PMID:31217188)
• Highly impaired platelet ultrastructure in two families with novel IKZF5 variants. (PMID:32419556)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ikzf5	ENSDARG00000056491
mus_musculus	Ikzf5	ENSMUSG00000040167
rattus_norvegicus	Ikzf5	ENSRNOG00000025651

Paralogs (38): ZFX (ENSG00000005889), ZBTB11 (ENSG00000066422), ZFAT (ENSG00000066827), ZFY (ENSG00000067646), ZNF586 (ENSG00000083828), ZNF419 (ENSG00000105136), ZNF549 (ENSG00000121406), ZSCAN20 (ENSG00000121903), ZNF304 (ENSG00000131845), PRDM15 (ENSG00000141956), ZNF660 (ENSG00000144792), ZNF711 (ENSG00000147180), ZNF773 (ENSG00000152439), ZNF256 (ENSG00000152454), ZNF837 (ENSG00000152475), ZNF691 (ENSG00000164011), ZNF610 (ENSG00000167554), E4F1 (ENSG00000167967), ZNF562 (ENSG00000171466), ZNF561 (ENSG00000171469), ZNF584 (ENSG00000171574), ZIK1 (ENSG00000171649), ZNF570 (ENSG00000171827), ZSCAN2 (ENSG00000176371), ZNF552 (ENSG00000178935), ZNF154 (ENSG00000179909), ZNF792 (ENSG00000180884), ZNF793 (ENSG00000188227), ZNF548 (ENSG00000188785), ZNF79 (ENSG00000196152), ZNF418 (ENSG00000196724), ZNF772 (ENSG00000197128), ZNF583 (ENSG00000198440), ZNF480 (ENSG00000198464), ZNF551 (ENSG00000204519), ZNF134 (ENSG00000213762), ZNF587B (ENSG00000269343), ZNF8 (ENSG00000278129)

Protein

Protein identifiers

Zinc finger protein Pegasus — Q9H5V7 (reviewed: Q9H5V7)

Alternative names: Ikaros family zinc finger protein 5

All UniProt accessions (1): Q9H5V7

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional repressor that binds the core 5’GNNTGTNG-3’ DNA consensus sequence. Involved in megakaryocyte differentiation.

Subunit / interactions. Self-associates. Interacts with other family members; IKZF1, IKZF2, IKZF3 and IKZF4.

Subcellular location. Nucleus.

Tissue specificity. Expressed in brain, heart, skeletal muscle, kidney, and liver. Expressed in the hematopoietic cell lines MOLT-4, NALM-6 and K-562. Highly expressed in THP-1 and M-07e cell lines, which have characteristics of myeloid and early megakaryocytic cells respectively.

Disease relevance. Thrombocytopenia 7 (THC7) [MIM:619130] A form of thrombocytopenia, a hematologic disorder defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. THC7 is an autosomal dominant form with highly variable severity, ranging from absence of bleeding symptoms to epistaxis or more severe bleeding episodes. The disease may be caused by variants affecting the gene represented in this entry.

Domain organisation. The N-terminal zinc fingers are involved in sequence-specific DNA binding and heterotypic associations with other family members. C-terminal zinc fingers mediate homodimerization.

Miscellaneous. ‘Pegasus’ was the winged horse in Greek mythology.

Similarity. Belongs to the Ikaros C2H2-type zinc-finger protein family.

RefSeq proteins (10): NP_001258769, NP_001359052, NP_001359053, NP_001359054, NP_001359055, NP_001359056, NP_001359057, NP_001359058, NP_001359059, NP_001359060 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050589	Ikaros_C2H2-ZF	Family

UniProt features (24 total): mutagenesis site 7, zinc finger region 5, compositionally biased region 4, cross-link 2, sequence variant 2, region of interest 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H5V7-F1	54.37	0.14

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 5, 185

Mutagenesis-validated functional residues (7):

Position	Phenotype
89	decreased protein abundance. decreased chromatin binding. decreased localization to the nucleus. tends to remain in the
96	decreased protein abundance. decreased chromatin binding. decreased localization to the nucleus. tends to remain in the
98	no effect on protein abundance. no effect on chromatin binding. no effect on localization to the nucleus.
134	decreased protein abundance. decreased chromatin binding. decreased localization to the nucleus. tends to remain in the
140	decreased protein abundance. decreased chromatin binding. decreased localization to the nucleus. tends to remain in the
155	decreased protein abundance. decreased chromatin binding. decreased localization to the nucleus. tends to remain in the
200	no effect on protein abundance. no effect on chromatin binding. no effect on localization to the nucleus.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 184 (showing top): YAATNRNNNYNATT_UNKNOWN, SP3_Q3, PAX2_01, WTGAAAT_UNKNOWN, TGIF_01, GARY_CD5_TARGETS_DN, MYOD_Q6, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, CUI_TCF21_TARGETS_2_DN, CART1_01, YNGTTNNNATT_UNKNOWN, GOMF_CHROMATIN_BINDING, TAATTA_CHX10_01, AHR_Q5, CAGTGTT_MIR141_MIR200A

GO Biological Process (2): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (10): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), chromatin binding (GO:0003682), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), protein domain specific binding (GO:0019904), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), protein-containing complex (GO:0032991)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
regulation of DNA-templated transcription	2
transcription cis-regulatory region binding	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
binding	2
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
cis-regulatory region sequence-specific DNA binding	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
transcription regulator activity	1
transition metal ion binding	1
protein binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1
cellular_component	1

Protein interactions and networks

STRING

826 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IKZF5	IPO11	Q9UI26	428
IKZF5	YEATS2	Q9ULM3	425
IKZF5	SH3BP5L	Q7L8J4	343
IKZF5	PUM3	Q15397	338
IKZF5	CWF19L1	Q69YN2	328
IKZF5	CBFA2T2	O43439	323
IKZF5	SLFN14	P0C7P3	307
IKZF5	HMGN3	Q15651	302
IKZF5	PIDD1	Q9HB75	297
IKZF5	TNPO1	Q92973	291
IKZF5	IKZF3	Q9UKT9	291
IKZF5	CRBN	Q96SW2	290
IKZF5	MED13L	Q71F56	288
IKZF5	YOD1	Q5VVQ6	282
IKZF5	ACADSB	P45954	281

IntAct

18 interactions, top by confidence:

A	B	Type	Score
IKZF5	IKZF3	psi-mi:“MI:0915”(physical association)	0.670
IKZF5	CCNB1	psi-mi:“MI:0914”(association)	0.640
IKZF1	IKZF5	psi-mi:“MI:0915”(physical association)	0.550
IKZF5	IKZF5	psi-mi:“MI:0915”(physical association)	0.370
Set	ZKSCAN1	psi-mi:“MI:0914”(association)	0.350
IKZF5	PEX14	psi-mi:“MI:0914”(association)	0.350
IKZF1	MTA2	psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
NPM1	RPS3A	psi-mi:“MI:0914”(association)	0.350
IKZF5	TADA2A	psi-mi:“MI:0914”(association)	0.350
AIM2	DDX39A	psi-mi:“MI:0914”(association)	0.350
ESR2	PSMD11	psi-mi:“MI:0914”(association)	0.350
LHX3	BCL9	psi-mi:“MI:2364”(proximity)	0.270
IKZF5	EEF1D	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (121): IKZF5 (Two-hybrid), IKZF5 (Two-hybrid), IKZF5 (Two-hybrid), IKZF5 (Two-hybrid), IKZF5 (Affinity Capture-MS), CHD8 (Affinity Capture-MS), MIB2 (Affinity Capture-MS), ZC3H3 (Affinity Capture-MS), IKZF2 (Affinity Capture-MS), IKZF3 (Affinity Capture-MS), AHDC1 (Affinity Capture-MS), CCDC77 (Affinity Capture-MS), TCF7L2 (Affinity Capture-MS), ZNF518B (Affinity Capture-MS), ZZZ3 (Affinity Capture-MS)

ESM2 similar proteins: A0JPB4, A1L1J6, A2VDW9, A4IFJ6, O00409, O08876, O08900, O13089, O15060, O15062, O42410, O57415, O60315, O75626, O89091, P14404, P25932, P36197, P37275, P55878, P55879, P81183, Q03267, Q0VDT2, Q13422, Q33BP8, Q3BJS3, Q3UH06, Q499D0, Q5R9W9, Q5T0B9, Q5ZLR2, Q5ZM39, Q60636, Q62255, Q62947, Q64318, Q6DBW0, Q6NRM0, Q6XDT4

Diamond homologs: A0JPB4, A2VDW9, A4IFJ6, H2L008, O08900, O13089, O42410, O62537, O62538, O62541, O96785, P05084, P13361, P81183, Q01778, Q01791, Q03267, Q13422, Q25514, Q5R9W9, Q5ZLR2, Q6DBW0, Q6NRM0, Q6XDT4, Q6XDT6, Q8BU00, Q8C208, Q90ZS6, Q925H1, Q9H2S9, Q9H5V7, Q9UHF7, Q9UKS7, Q9UKT9, Q9BLC4, Q9HCK0, Q5JPB2, Q65XX7, O18326, O46232

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
IKZF5	“up-regulates quantity by expression”	LNPEP	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	2
Uncertain significance	15
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1684455	NM_001372123.1(IKZF5):c.463C>T (p.His155Tyr)	Pathogenic
1684456	NM_001372123.1(IKZF5):c.418T>C (p.Cys140Arg)	Pathogenic
1703863	NM_001372123.1(IKZF5):c.362A>T (p.Tyr121Phe)	Likely pathogenic
2671954	NM_001372123.1(IKZF5):c.296_300delinsTGTGGATT (p.Glu99_His100delinsValTrpIle)	Likely pathogenic

SpliceAI

1032 predictions. Top by Δscore:

Variant	Effect	Δscore
10:122995988:CATTA:C	donor_loss	1.0000
10:122995992:ACC:A	donor_loss	1.0000
10:122995993:CC:C	donor_loss	1.0000
10:122996172:TCCAG:T	acceptor_gain	1.0000
10:122996173:CCAG:C	acceptor_gain	1.0000
10:122996173:CCAGC:C	acceptor_gain	1.0000
10:122996174:CAG:C	acceptor_gain	1.0000
10:122996174:CAGC:C	acceptor_gain	1.0000
10:122996175:AG:A	acceptor_gain	1.0000
10:122996177:C:CC	acceptor_gain	1.0000
10:122996179:A:C	acceptor_gain	1.0000
10:122996184:C:CT	acceptor_gain	1.0000
10:122996185:A:T	acceptor_gain	1.0000
10:122996188:G:C	acceptor_gain	1.0000
10:122996192:C:CT	acceptor_gain	1.0000
10:122996192:C:T	acceptor_gain	1.0000
10:122998494:T:TA	donor_gain	1.0000
10:123008689:CTTA:C	donor_loss	1.0000
10:123008690:TTACC:T	donor_loss	1.0000
10:123008691:TACC:T	donor_loss	1.0000
10:123008692:A:AC	donor_gain	1.0000
10:123008692:ACCT:A	donor_gain	1.0000
10:123008693:C:CC	donor_gain	1.0000
10:123008693:CCT:C	donor_gain	1.0000
10:123008693:CCTC:C	donor_gain	1.0000
10:122994720:TCACC:T	acceptor_loss	0.9900
10:122994722:ACC:A	acceptor_loss	0.9900
10:122994723:CCTGT:C	acceptor_loss	0.9900
10:122994724:C:CG	acceptor_loss	0.9900
10:122994725:T:C	acceptor_loss	0.9900

AlphaMissense

2807 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:122994605:G:C	F145L	1.000
10:122994605:G:T	F145L	1.000
10:122994607:A:G	F145L	1.000
10:122994622:A:G	C140R	1.000
10:122994651:C:G	R130P	1.000
10:122994658:G:C	H128D	1.000
10:122994666:A:G	L125P	1.000
10:122994689:A:C	F117L	1.000
10:122994689:A:T	F117L	1.000
10:122994691:A:G	F117L	1.000
10:122994695:A:C	C115W	1.000
10:122994697:A:G	C115R	1.000
10:122994706:A:G	C112R	1.000
10:122996010:G:C	H100Q	1.000
10:122996010:G:T	H100Q	1.000
10:122996020:A:G	L97P	1.000
10:122996049:G:C	C87W	1.000
10:122996060:A:G	C84R	1.000
10:122993860:A:G	C394R	0.999
10:122993942:G:C	C366W	0.999
10:122993944:A:G	C366R	0.999
10:122994574:G:C	H156D	0.999
10:122994582:A:G	L153S	0.999
10:122994599:G:C	C147W	0.999
10:122994601:A:G	C147R	0.999
10:122994606:A:G	F145S	0.999
10:122994611:A:C	C143W	0.999
10:122994612:C:T	C143Y	0.999
10:122994613:A:G	C143R	0.999
10:122994620:A:C	C140W	0.999

dbSNP variants (sampled 300 via entrez): RS1000031405 (10:123004933 A>C,G), RS1000048298 (10:123002806 C>A), RS1000547978 (10:123004586 C>T), RS1000587053 (10:122991926 T>A), RS1000860936 (10:122999707 A>G,T), RS1000872216 (10:123006312 G>A,C), RS1001205784 (10:122991178 C>G,T), RS1001243828 (10:122998095 C>A,T), RS1001300456 (10:122990343 T>A,C), RS1001314278 (10:122997774 T>A), RS1001440292 (10:123006523 ATCTTCCT>A), RS1001472198 (10:123004757 T>A,C), RS1001603438 (10:123005060 G>A,T), RS1001773684 (10:122990661 G>A), RS1001881864 (10:122998217 T>C)

Disease associations

OMIM: gene MIM:606238 | disease phenotypes: MIM:610006, MIM:619130, MIM:618250

GenCC curated gene-disease

Disease	Classification	Inheritance
thrombocytopenia 7	Strong	Autosomal dominant
autosomal thrombocytopenia with normal platelets	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
thrombocytopenia 7	Moderate	AD

Mondo (4): 2-methylbutyryl-CoA dehydrogenase deficiency (MONDO:0012392), thrombocytopenia 7 (MONDO:0030867), mitochondrial complex I deficiency, nuclear type 29 (MONDO:0032633), (MONDO:0015679)

Orphanet (1): 2-methylbutyryl-CoA dehydrogenase deficiency (Orphanet:79157)

HPO phenotypes

9 total (9 of 9 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001873	Thrombocytopenia
HP:0004866	Impaired ADP-induced platelet aggregation
HP:0008320	Impaired collagen-induced platelet aggregation
HP:0011870	Impaired arachidonic acid-induced platelet aggregation
HP:0011871	Impaired ristocetin-induced platelet aggregation
HP:0011891	Post-partum hemorrhage
HP:0033535	Reduced platelet dense granules
HP:0033536	Reduced platelet alpha granules

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C566487	2-Methylbutyryl-CoA Dehydrogenase Deficiency (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression	3
Cisplatin	decreases expression, increases expression	2
Valproic Acid	affects expression, decreases expression	2
GSK-J4	increases expression	1
TAK-243	decreases sumoylation	1
methylmercuric chloride	decreases expression	1
beta-lapachone	increases expression, decreases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
resorcinol	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
cylindrospermopsin	increases expression	1
dimethylarsinous acid	increases expression	1
abrine	increases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Air Pollutants, Occupational	affects expression	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Doxorubicin	decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Ozone	affects expression, increases abundance	1
Urethane	increases expression	1
Aflatoxin B1	decreases methylation	1
Asbestos, Crocidolite	increases expression	1
Antirheumatic Agents	increases expression	1
Copper Sulfate	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A3E1	SEES3-1V human IKZF5, clone1	Embryonic stem cell	Male
CVCL_A3E2	SEES3-1V human IKZF5, clone2	Embryonic stem cell	Male
CVCL_A3E3	SEES3-1V human IKZF5, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05910151	Not specified	UNKNOWN	Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan